MX2012006512A - Metodos y reactivos para la deteccion mejorada de peptidos beta amiloides. - Google Patents

Metodos y reactivos para la deteccion mejorada de peptidos beta amiloides.

Info

Publication number
MX2012006512A
MX2012006512A MX2012006512A MX2012006512A MX2012006512A MX 2012006512 A MX2012006512 A MX 2012006512A MX 2012006512 A MX2012006512 A MX 2012006512A MX 2012006512 A MX2012006512 A MX 2012006512A MX 2012006512 A MX2012006512 A MX 2012006512A
Authority
MX
Mexico
Prior art keywords
methods
neurodegenerative disease
amyloid beta
reagents
beta peptides
Prior art date
Application number
MX2012006512A
Other languages
English (en)
Inventor
Barrio Jose Manuel Sarasa
Original Assignee
Araclon Biotech Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araclon Biotech Sl filed Critical Araclon Biotech Sl
Publication of MX2012006512A publication Critical patent/MX2012006512A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La invención se refiere a métodos para el diagnóstico de una enfermedad neurodegenerativa, para la detección de una etapa antes de una enfermedad neurodegenerativa o para distinguir la enfermedad neurodegenerativa de una etapa antes de una enfermedad neurodegenerativa con base en el nivel de ciertas concentraciones de péptidos beta amiloides que o bien se enlazan a los componentes de plasma o bien se enlazan a las células sanguíneas, así como en ciertos parámetros calculados que se obtienen mediante una combinación aritmética de uno o más de los niveles del péptido amiloide. La invención se refiere igualmente a kits para llevar a cabo el método anterior.
MX2012006512A 2009-12-11 2010-12-13 Metodos y reactivos para la deteccion mejorada de peptidos beta amiloides. MX2012006512A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382279 2009-12-11
PCT/EP2010/069474 WO2011070174A1 (en) 2009-12-11 2010-12-13 Methods and reagents for improved detection of amyloid beta peptides

Publications (1)

Publication Number Publication Date
MX2012006512A true MX2012006512A (es) 2012-08-17

Family

ID=41818879

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006512A MX2012006512A (es) 2009-12-11 2010-12-13 Metodos y reactivos para la deteccion mejorada de peptidos beta amiloides.

Country Status (21)

Country Link
US (2) US20120264642A1 (es)
EP (1) EP2510359B1 (es)
JP (1) JP5745531B2 (es)
KR (1) KR101531949B1 (es)
CN (1) CN102713633B (es)
AR (1) AR079443A1 (es)
AU (1) AU2010329844B2 (es)
BR (1) BR112012014060B8 (es)
CA (1) CA2782250C (es)
DK (1) DK2510359T3 (es)
ES (1) ES2552627T3 (es)
HK (1) HK1175242A1 (es)
HU (1) HUE028105T2 (es)
IL (1) IL220276A (es)
IN (1) IN2012DN05056A (es)
MX (1) MX2012006512A (es)
PL (1) PL2510359T3 (es)
PT (1) PT2510359E (es)
RU (1) RU2554774C2 (es)
TW (1) TWI509246B (es)
WO (1) WO2011070174A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140128229A (ko) * 2013-04-26 2014-11-05 한국과학기술연구원 체내 단백질 응집체의 용해를 이용한 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환 또는 질병을 진단하는 혈액진단키트
WO2015178398A1 (ja) * 2014-05-22 2015-11-26 株式会社 島津製作所 脳内のアミロイドβペプチド蓄積状態を評価するサロゲート・バイオマーカー及びその分析方法
AU2015311836B2 (en) * 2014-09-05 2021-03-11 Presympto, Inc. Methods for detecting amyloid beta oligomers
KR101786859B1 (ko) * 2015-04-30 2017-10-17 서울대학교산학협력단 혈장 내 아밀로이드베타의 농도를 통해 알츠하이머병을 임상학적 및 병리학적으로 모니터링하는 방법
RU2611408C1 (ru) * 2015-09-23 2017-02-21 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Чувашский государственный университет имени И.Н. Ульянова" Способ флуоресцентного гистологического выявления амилоида
GB201518675D0 (en) * 2015-10-21 2015-12-02 Cellcap Technologies Ltd Detection of structural forms of proteins
WO2019167128A1 (ja) * 2018-02-27 2019-09-06 株式会社 島津製作所 サンドイッチ型免疫測定法
JP7434144B2 (ja) * 2018-02-27 2024-02-20 株式会社島津製作所 ＡＰＰ６６９－ｘのＮ末端を特異的に認識する抗体、及び免疫測定法
RU2708465C1 (ru) * 2019-02-18 2019-12-09 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Способ детекции модификаций амилоидного пептида с помощью высокоспецифичных антител
WO2020179224A1 (ja) * 2019-03-01 2020-09-10 株式会社島津製作所 Ａｐｐ６６９－７１１の測定方法、及び測定用キット
GB201904810D0 (en) 2019-04-05 2019-05-22 Cynapsedx Ltd The treatment of protein aggregation diseases
BR112021022421A2 (pt) * 2019-05-10 2021-12-28 Quest Diagnostics Invest Llc Ensaio multiplex para determinar a razão de ss-amiloide 42/40 em espécimes de plasma humano
WO2021009074A1 (en) 2019-07-12 2021-01-21 Adx Neurosciences Nv Novel markers as early predictors of alzheimer's pathology
CN116574271B (zh) * 2023-06-06 2023-12-19 苏州谱迪生物科技有限公司 一种用于免疫检测低丰度生物标志物信号级联放大的荧光树状大分子的制备方法及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976817A (en) * 1996-10-31 1999-11-02 Trustees Of Boston University Diagnostic method for detecting Alzheimer's disease in living patients
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
NZ520800A (en) 2000-02-24 2004-04-30 Univ Washington Humanised monoclonal antibodies that sequester amyloid beta peptide so as to prevent its deposition in the brain
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
JP4511830B2 (ja) 2001-08-17 2010-07-28 ワシントン・ユニバーシティ アルツハイマー病のアッセイ方法
EP1523499A2 (en) 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
ES2201929B1 (es) 2002-09-12 2005-05-16 Araclon Biotech, S.L. Anticuerpos policlonales, metodo de preparacion y uso de los mismos.
US20040096907A1 (en) * 2002-11-06 2004-05-20 Bernd Bohrmann Quantification of beta amyloid
ES2246105B1 (es) 2003-05-08 2007-03-01 Araclon Biotech, S.L. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
EP1480041A1 (en) * 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
JP4668191B2 (ja) * 2003-08-20 2011-04-13 アモールフィックス・ライフ・サイエンシィズ・リミテッド タンパク質立体配座を検出するためのエピトープ保護アッセイおよび方法
KR20070073778A (ko) 2004-10-28 2007-07-10 산코 준야쿠 가부시키가이샤 알츠하이머병의 검정방법 및 진단시약
EP1820019A4 (en) 2004-11-12 2008-05-14 Pfizer METHOD FOR MEASURING BETA-AMYLOID PEPTIDES
WO2007022015A1 (en) 2005-08-12 2007-02-22 Georgetown University Methods to evaluate amyloid beta-lowering agents using wild-type mice
JP5289963B2 (ja) 2005-10-21 2013-09-11 メルク・シャープ・アンド・ドーム・コーポレーション 抗ａｄｄｌモノクローナル抗体およびその使用
EP2020602A1 (en) 2007-08-02 2009-02-04 Araclon Biotech High sensitivty immunoassays and kits for the determination of peptides and proteins of biological interest
US20090246191A1 (en) * 2007-10-11 2009-10-01 University Of Tennessee Research Foundation Preparation of Purified Covalently Cross-linked Abeta Oligomers and Uses Thereof
CA2779565A1 (en) * 2009-11-24 2011-06-03 Probiodrug Ag Novel diagnostic method for the diagnosis of alzheimer's disease or mild cognitive impairment

Also Published As

Publication number Publication date
PL2510359T3 (pl) 2016-02-29
RU2012129184A (ru) 2014-01-20
PT2510359E (pt) 2015-12-02
ES2552627T3 (es) 2015-12-01
CN102713633B (zh) 2015-03-11
EP2510359B1 (en) 2015-09-02
JP5745531B2 (ja) 2015-07-08
HK1175242A1 (en) 2013-06-28
AR079443A1 (es) 2012-01-25
EP2510359A1 (en) 2012-10-17
US20210011032A1 (en) 2021-01-14
JP2013513791A (ja) 2013-04-22
BR112012014060B1 (pt) 2021-01-19
BR112012014060B8 (pt) 2021-07-27
CA2782250C (en) 2016-08-30
AU2010329844A1 (en) 2012-06-14
IL220276A0 (en) 2012-07-31
TW201131167A (en) 2011-09-16
CN102713633A (zh) 2012-10-03
RU2554774C2 (ru) 2015-06-27
IN2012DN05056A (es) 2015-10-09
KR20120115306A (ko) 2012-10-17
AU2010329844B2 (en) 2015-07-16
CA2782250A1 (en) 2011-06-16
WO2011070174A1 (en) 2011-06-16
DK2510359T3 (en) 2015-12-07
BR112012014060A2 (pt) 2016-12-13
IL220276A (en) 2016-02-29
TWI509246B (zh) 2015-11-21
HUE028105T2 (en) 2016-11-28
US20120264642A1 (en) 2012-10-18
KR101531949B1 (ko) 2015-06-26

Similar Documents

Publication Publication Date Title
MX2012006512A (es) Metodos y reactivos para la deteccion mejorada de peptidos beta amiloides.
CY1123172T1 (el) Δοκιμασια για συλληψη και ανιχνευση κυκλοφορουντων κυτταρων πολλαπλου μυελωματος απο αιμα
WO2010088411A3 (en) Conformationally dynamic peptides
MX337535B (es) Anticuerpo, kit y metodo para la determinacion de peptidos amiloides.
MX341840B (es) Biomarcadores de microarn indicativos de la enfermedad de alzheimer.
PH12015502849A1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
WO2010099342A3 (en) Methods of detecting lung cancer
WO2011136624A3 (ko) 자기장 인가부를 구비한 생물학적 시료 자동정제장치, 생물학적 시료로부터 타겟물질을 추출하는 방법, 그리고 단백질 발현 및 정제 방법
IL225386A (en) A method for identifying cancer by identifying ereg protein
EP2829881A3 (en) Diagnostic for colorectal cancer
GB201216076D0 (en) Methods for obtaining a sequence
WO2011031786A3 (en) Compositions and methods for diagnosing autism spectrum disorders
MX2013012183A (es) Terapia de combinacion de hsp90.
WO2010083347A3 (en) Peptidomimetic macrocycles
GB0603251D0 (en) DNA conformation
IL214434A (en) A method for separating an antibody or protein containing an antibody fragment from one or more contaminants
WO2010102195A3 (en) Annexin a11 and associated genes as biomarkers for cancer
EA200801942A1 (ru) Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон
CA2839777C (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
WO2010115745A3 (en) Biomarkers, methods and kits for the diagnosis of rheumatoid arthritis
WO2012167086A3 (en) Methods of diagnosing and treating amyotrophic lateral sclerosis
MX2018005448A (es) Metodos para la deteccion de apolipoproteinas.
WO2010144553A3 (en) Methods for diagnosing blood vessel reocclusion
AU2012339149A8 (en) Method for the diagnosis of Niemann-Pick disease

Legal Events

Date Code Title Description
FG Grant or registration